Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date: December 12, 2024
Subject: Compliance with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity.
Key Financial Metrics
- Stockholders' Equity (Current): Approximately $6.0 million.
- Cash and Cash Equivalents: $7.1 million.
- Stockholders' Equity (Q3 2024): $2,673,617 (per Form 10-Q).
- Stockholders' Equity (Q2 2024): $1,140,421 (per Form 10-Q).
- Transaction Proceeds: Approximately $4.1 million gross proceeds from warrant exercises.
Material Changes
The Company previously received notice from Nasdaq on August 14, 2024, of non-compliance with the $2.5 million minimum stockholders' equity requirement based on Q2 2024 results. While Q3 2024 results showed temporary compliance, the Company executed a warrant exercise inducement offer on December 3, 2024. Holders exercised 4,064,040 existing Class E warrants at $1.00 per share. In exchange, the Company issued new Class F and Class G warrants. This transaction increased stockholders' equity to approximately $6.0 million, restoring compliance with Nasdaq listing standards.
Outlook, Risks, and Management Commentary
Management states the Company is now in compliance with the Stockholders' Equity Requirement. The warrant issuance was structured as an at-market transaction under Nasdaq rules. The filing does not provide specific forward-looking guidance on revenue, profit, or operational milestones beyond the immediate capital raise. The primary risk addressed was the potential delisting due to insufficient equity, which has been mitigated by the recent capital infusion.
Investor Verification Checklist
- Verify the exact number of new Class F and Class G warrants issued and their specific terms (exercise price, expiration).
- Confirm the deduction of financial advisory fees from the $4.1 million gross proceeds to determine net cash impact.
- Review the Company's cash burn rate to assess the runway provided by the $7.1 million cash balance.
- Monitor future 10-Q filings to ensure sustained compliance with the $2.5 million equity threshold.